NOW ENROLLING PHASE III sunRIZE TRIAL In the study of congenital hyperinsulinism

Learn More »

Investors & Media
Contact Us

Therapeutic Focus
For Patients
About
Join Us
Contact Us
Investors & Media

Investors & Media|
- Overview|
- Corporate Presentation|
- News|
- Events|
- Stock Quote and Chart|
  - Historical Data|
- Analyst Coverage|
- SEC Filings|
- Governance|
- Info|
Contact Us|

Rezolute Announces Further Evidence of RZ358’s Efficacy in Tumor-Mediated Hyperinsulinism

Back to Careers

Stay Connected

Email Alerts Contacts RSS News Feed

©2024 Rezolute, Inc.

Explore

Therapeutic Focus
For Patients
About
Join Us
Contact Us
Investors & Media

Contact

Corporate Headquarters

275 Shoreline Drive
Suite 500
Redwood City, CA 94065

+1 (650) 206-4507
info@rezolutebio.com

Investor Relations

Oregon Office
2783 NW Lolo Drive
Suite 150
Bend, OR 97703

Legal

Terms of Use
Privacy Policy

MENU

Therapeutic Focus
For Patients
About
Join Us
Contact Us
Investors & Media